2029 Biosimilars Disease 
Vial
MARCH 1, 2024
Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,
Drug Discovery World
JULY 26, 2024
Conversely, Trump champions free market competition and biosimilars. His 2018 law bolstering the US Federal Trade Commission’s (FTC’s) oversight of biosimilar deals, aimed to increase competition for expensive biologics. With an anticipated annual growth rate of 7.61%, they are predicted to reach US$12.57bn by 2029.
Expert insights. Personalized for you.
52 
Let's personalize your content